ArticleInternational journal of women's health2026
Targeted Duct Excision Reduces Recurrence and Shortens Treatment Duration in Periductal Mastitis: A Retrospective Cohort Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Staged topical herbal therapy for giant plasma cell mastitis in pregnancy with 3-year follow-up.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Periductal mastitis (PDM) is characterized by prolonged treatment and high recurrence, yet no large-scale study has identified its recurrence risk factors. Methods: A total of 150 treatment-naïve patients diagnosed with PDM at the Third People's Hospital of Chengdu from January 2019 to March 2025 were retrospectively included. Univariate and multivariate Cox regression analyses were used to identify factors associated with recurrence; Kaplan-Meier and log-rank tests assessed recurrence-free survival. Baseline patient characteristics, along with treatment duration, time to recurrence, and cosmetic outcomes, were systematically recorded. Results: Targeted duct excision was the only independent protective factor against recurrence (adjusted HR = 0.09, 95% CI: 0.04-0.20; Conclusion: In patients with PDM, targeted duct excision significantly reduces recurrence risk, shortens treatment duration, and preserves breast appearance, suggesting that this surgical approach should be considered as the primary treatment option for PDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.